MedTrace Logo

Evaluation of Paclitaxel Coated Balloon in the Treatment of Dialysis Access Dysfunction

NCT04988789 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2021-08-04

No results posted yet for this study

Summary

Recent studies of paclitaxel DCB in the treatment of stenosis at dialysis vascular access have shown promising results. Paclitaxel, an anti-proliferation drug, is released during balloon inflation and potentially improve primary patency by slowing down NIH effect. However, meta-analysis have suggested that the use of paclitaxel in lower limbs have increased risk of death in patients. The effect of paclitaxel DCB on dialysis access however remains unknown. Hence, we aim to set up a database to track long-term treatment outcomes of patients treated with Paclitaxel DCB at SGH for their stenosed dialysis access

Conditions

Interventions

DRUG

Paclitaxel Drug Coated Balloon

Failing AVF/AVGs treated with Paclitaxel Drug Coated balloons are captured in this database

Sponsors & Collaborators

  • Singapore General Hospital

    lead OTHER

Principal Investigators

  • Tang Tjun Yip · Singapore General Hospital

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04988789 on ClinicalTrials.gov